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ABSTRACT
During a 12-month surveillance period, haemodialysis (HD) patients in southern Israel were categorised
according to the type of vascular access site (VAS), i.e., arteriovenous (AV) fistula, synthetic AV graft, and
cuffed or non-cuffed vascular catheters. Endpoints, expressed as cases ⁄ 100 patient-months, were:
incidence of hospital admission; antibiotic therapy; bloodstream infection (BSI); and VAS infection. These
were compared to Centers for Disease Control (CDC) surveillance data, overall and by VAS type. In total,
2568 patient-months were analysed. The VAS distribution differed significantly from CDC data for
fistulas (72% vs. 31%), grafts (12% vs. 41%), cuffed catheters (11% vs. 25%) and non-cuffed catheters (5%
vs. 3%) (p < 0.0001 in all cases). Of 151 admissions, 32% resulted from infection, for which 112 antibiotic
courses (22% vancomycin) were given. There were 16 BSIs, three involving resistant strains. The
incidences of admission, antibiotic therapy, BSI and VAS infection were significantly lower overall,
compared to CDC rates, as were most VAS-specific endpoints. These differences may be explained by
VAS type distribution, although other factors may also be involved. Reporting regional or national
surveillance data may allow a standardised comparison of the incidence of HD-associated infections.
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INTRODUCTION
Millions of patients worldwide are being treated
with haemodialysis (HD) as a result of chronic
end-stage renal disease. HD patients are at high
risk of infection because of impaired immune
status, severity of illness and frequent puncture of
the vascular access site (VAS) during HD [1].
Infections among HD patients may lead to sub-
stantial morbidity and mortality, with increased
utilisation of healthcare resources and related
costs. In addition, antibiotic use may be increased
in the HD setting, leading to the emergence of
antibiotic-resistant bacteria, including vancomy-
cin-resistant staphylococci [2] and enterococci [3].
For the above reasons, routine surveillance of
HD-associated infections is important; indeed,
such surveillance is currently taking place in
many countries, including the USA, in which a
national surveillance network for HD patients
was instituted in 1999 [4]. However, there are no
data regarding the incidence of HD-associated
infections in Israel. Therefore, the aim of this
study was to present the results of regional
surveillance of HD-associated infections in south-
ern Israel.
PATIENTS AND METHODS
During the 12-month period October 2002-September 2003, all
adult HD patients treated at the Soroka University Medical
Center (SUMC) were included in a prospective surveillance
study. This institution is a tertiary-care referral centre provi-
ding HD services for the entire population of the Negev area
(> 500 000 inhabitants). All dialysed patients were Negev area
residents.
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Surveillance was performed by an infection control nurse.
Data were collected as census (denominator), expressed as
patient-months, and incidents (numerators), including occur-
rence of hospital admission (and its cause), occurrence of
infections (by anatomical site), infection associated with
antibiotic-resistant bacteria, and antibiotic use. Infections
(urinary tract infection, pneumonia, wound infection, blood-
stream infection (BSI), VAS infection and fever without source)
were diagnosed according to Centers for Disease Control
(CDC) definitions [4]. Data regarding the clinical indication for
HD, as well as underlying medical disorders, were collected
from medical records for each dialysed patient.
Patients were categorised according to the type of VAS,
namely arteriovenous (AV) fistulas (created from native
vessels), synthetic AV grafts, and cuffed (permanent) or non-
cuffed (temporary) vascular catheters. The risk for admission
caused by infection was analysed according to the type of VAS.
Statistical significance was determined using the chi-square
and two-tailed Fisher’s exact tests, as appropriate. A p value of
< 0.05 was considered statistically significant. Odds ratios were
calculated for significant variables. Rates of admission and
infection were compared with the data reported by the CDC
[4]. Main endpoints were the incidence of hospital admission,
need for intravenous antibiotic therapy, incidence of BSI and
incidence of VAS infection.
RESULTS
Between 199 and 224 HD patients were dialysed
each month, with a total of 2568 patient-months.
The mean age of the study patients was
63.5 ± 15 years (median 68 years; range 15–
89 years) and 55.2% were males. The clinical
indications for HD were: diabetic nephropathy
(39%), hypertensive nephropathy (17%), secon-
dary glomerulonephritis (10%), idiopathic glome-
rulonephritis (6%), atherosclerosis (6%), renal
amyloidosis (3%), polycystic kidney disease (3%),
renal vasculitis (3%), nephrocalcinosis (2%), reflux
nephropathy (2%), obstructive uropathy (1%) and
interstitial nephritis (1%). Diagnosis of underlying
kidney disease remained uncertain in 7% of cases.
Underlying medical disorders among study
patients were: dyslipidaemia (50%), diabetes
mellitus (48%), ischaemic heart disease (44%),
arterial hypertension (38%), diabetic foot (21%),
congestive heart failure (21%), cardiac arrhyth-
mias (18%), chronic hepatitis C virus infection
(15%), valvular heart disease (10%), severe
anaemia (10%), chronic lung disease (9%), previ-
ous stroke (5%) and malignancy (5%). Other
more rare diagnoses (affecting < 2%) were present
in 20% of the patients. These included systemic
amyloidosis, inflammatory bowel disease, various
autoimmune and collagen vascular diseases, and
thyroid and parathyroid disorders.
The distribution of the census according to the
type of VAS is shown in Table 1. Fistula was the
most common VAS among the study patients.
Compared to the CDC census data, HD patients at
SUMC were significantly more likely to be dia-
lysed using fistula (and to a lesser, but significant,
extent using non-cuffed catheters), and were
significantly less likely to be dialysed using grafts
or cuffed catheters.
During the study period, 151 HD patients were
admitted. Admitting wards were nephrology
(64.2%), internal medicine (24.5%), general sur-
gery (2.7%), gynaecological surgery (2.7%) and
other (5.9%). Most (68%) admissions were asso-
ciated with non-infectious disorders, including
cardiovascular problems as well as non-infectious
VAS problems (Table 2). Of admissions resulting
from infection (32%), most (76.6%) were associ-
ated with fever, but without an infectious focus
present at admission, while there was a distinct
infectious focus in 23.4% (comprising 7.3% of
overall admissions) of cases. VAS infection
accounted for 2% of admissions (or 6.4% of
admissions caused by infection).
BSI (either VAS-related or BSI associated with
another source) was detected in 16 cases (10.6% of
admissions), of which 12 were monomicrobial
Table 1. Number of patient-months (denominator)
according to vascular access site at the Soroka University
Medical Center, compared with data from the Centers for
Disease Control [4]
VAS type SUMC (%) CDC (%) p value/OR
Fistula 1855 (72.2) 23 340 (30.9) < 0.0001 ⁄ 5.8
Graft 300 (11.7) 30 844 (40.9) < 0.0001 ⁄ 0.19
Cuffed catheter 274 (10.7) 18 959 (25.1) < 0.0001 ⁄ 0.36
Non-cuffed catheter 122 (4.7) 2342 (3.1) < 0.0001 ⁄ 1.56
Total 2568 (100%) 75 535 (100%) –
VAS, vascular access site; SUMC, Soroka University Medical Center; CDC, Centers
for Disease Control and Prevention; OR, odds ratio.
Table 2. Diagnoses at admission of study patients
(n = 151)
Diagnosis Frequency
Infectious
Fever without source 24%
VAS infection 2%
Non-VAS wound infection 3%
Pneumonia 1%
Urinary tract infection 2%
Non-infectious
Other diagnoses (non-infectious) 44%
Cardiovascular events 10%
VAS problem (non-infectious) 14%
VAS, vascular access site.
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infections and four were polymicrobial. Overall,
21 microorganisms were isolated from BSI cases,
of which 57.2% were Gram-positive bacteria,
38.3% Gram-negative bacteria, and 4.5% yeasts
(Table 3). Three BSI cases involved antibiotic-
resistant pathogens, i.e., methicillin-resistant Sta-
phylococcus aureus (MRSA) and multiresistant
Acinetobacter baumannii and Pseudomonas aerugi-
nosa (both susceptible only to carbapenems and
polymyxin). All Gram-positive isolates were
vancomycin-susceptible.
The incidence rates (cases ⁄ 100 patient-months)
for the study endpoints were 5.9 for hospital
admissions, 2.5 for intravenous antibiotic therapy,
0.6 for BSI and 0.1 for VAS infection (Table 4).
Compared to CDC data, this study population
had a significantly lower incidence of hospital
admission, intravenous antibiotic therapy, BSI
and VAS infection.
VAS-specific incidence rates for the study
endpoints are shown in Table 4. The incidence
of hospitalisation was significantly lower in
SUMC compared to the CDC census for all types
of VAS. The incidence of intravenous antibiotic
therapy was similar, except for a significantly
lower incidence in SUMC patients dialysed using
cuffed catheters. SUMC patients dialysed using a
fistula or cuffed catheters had a significantly
lower incidence of BSI. Moreover, all VAS, except
for grafts, were associated at SUMC with a
significantly lower incidence of VAS infection.
Antibiotic utilisation among study patients is
depicted in Fig. 1. In total, 112 antibiotic courses
were given to 65 admitted patients. One course
was given to 33 patients, two courses to 17
patients, and three courses to 15 patients. Vanco-
mycin was given to 22% of patients, and 38%
received a b-lactam (cephalosporin, b-lactamase
inhibitor-containing preparation or carbapenem).
DISCUSSION
The number of HD patients in the USA has
increased sharply during the past 30 years. In
1999, > 3000 HD centres had > 190 000 HD
patients and > 60 000 staff members [5]. HD
patients are at risk of infection because of the
requirement for vascular access for prolonged
periods, and repeated opportunities for cross-
transmission of pathogens person-to-person or
Table 3. Species distribution of pathogens isolated from
the blood of haemodialysis patients at Soroka University
Medical Center (n = 21)
Species Frequency (%)
Methicillin-susceptible Staphylococcus aureus 28
Coagulase-negative Staphylococcus spp. 13
Escherichia coli 14
Methicillin-resistant Staphylococcus aureus 10
Acinetobacter baumannii 10
Enterococcus faecalis 5
Pseudomonas aeruginosa 5
Proteus spp. 5
Enterobacter cloacae 5
Candida albicans 5
Table 4. Comparison of incidence rates (cases ⁄ 100 patient-months) at Soroka University Medical Center with data from
the Centers for Disease Control [4]
Incident
Fistula Graft Cuffed catheter Non-cuffed catheter All types
SUMC CDC p value/OR SUMC CDC p value/OR SUMC CDC p value/OR SUMC CDC p value/OR SUMC CDC p value/OR
Denominator 1867 23 333 – 302 30 903 – 276 18 928 – 123 2371 – 2568 75 535 –
Hospital
admission
4.55 9.4 < 0.001 ⁄ 0.46 4.33 12.9 < 0.001 ⁄ 0.3 10.5 20.5 < 0.001 ⁄ 0.45 19.5 32 0.003 ⁄ 0.5 5.9 14.3 < 0.001 ⁄ 0.05
Antibiotic
therapy
1.7 2 0.35 1.66 2.4 0.4 4.3 7.9 0.03 ⁄ 0.53 1.3 7.8 0.06 2.5 3.8 0.007 ⁄ 0.65
BSI 0.16 0.5 0.032 ⁄ 0.31 0 0.95 0.12 2.17 5.8 0.01 ⁄ 0.36 5.7 9.95 0.12 0.6 2.3 < 0.001 ⁄ 0.26
VAS infection 0.05 0.56 0.003 ⁄ 0.1 0.33 1.36 0.2 0.36 8.4 < 0.001 ⁄ 0.04 0 12 < 0.001 ⁄ < 0.01 0.1 3.2 < 0.001 ⁄ 0.04
SUMC, Soroka University Medical Center; CDC, Centers for Disease Control and Prevention; BSI, bloodstream infection; VAS, vascular access site; OR, odds ratio.
Fig. 1. Antibiotics given to haemodialysis patients.
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via contaminated devices, equipment and sup-
plies. Furthermore, HD patients are immunosup-
pressed and require frequent hospitalisation and
surgery, which increases exposure to nosocomial
infections.
The annual mortality rate among HD patients is
23%. Infections are the second most common
cause of mortality, accounting for 15% of deaths
[5], with sepsis being the most common infectious
cause of mortality. Several studies have shown
that BSI occurs in 0.63–1.7% patients ⁄month, and
VAS infections (with or without BSI) in 1.3–7.2%
patients ⁄month [6–9]. Among French HD
patients, 28% of 230 HD-associated infections
involved the VAS [6]. Thus, the VAS may be the
most common site for infection, and can cause
disseminated BSI or loss of vascular access.
The present study evaluated the incidence of
HD-associated infection in our institution by
means of the same surveillance method applied
by the CDC in the USA. The overall incidences of
hospital admission, intravenous antibiotic ther-
apy, BSI and VAS infection at SUMC were
significantly lower than those reported by the
CDC. There may be several possible explanations
for these findings.
First, underlying diseases are among the most
important risk factors for HD-associated infec-
tions. Therefore, differences in the case-mix may
account for differences in study endpoints. The
present study population was typical of devel-
oped countries, with diabetic nephropathy rank-
ing first among the indications for HD (nearly
40% of cases). However, CDC census data do not
include the prevalence of underlying diseases and
dialysis indications, and therefore it is impossible
to rule out any influence of intrinsic risk factors
for HD-associated infections.
Second, the type of VAS has the greatest
influence on bacterial infectious morbidity in
HD patients, with catheters posing the highest
risk for infection, grafts intermediate risk, and
native AV fistulas the lowest risk [8]. A study in
the USA has shown that, compared to AV fistula,
the risk of VAS infection was 2.2 with AV grafts,
13.6 with cuffed catheters, and 32.6 with non-
cuffed catheters [10]. Similar differences are also
evident from CDC data [4] and available recom-
mendations [5]. These data support the guidelines
issued in 2001 by the National Kidney Foundation
[11]. These guidelines, which have been adopted
worldwide, suggest that at least 40% of HD
patients should have a native AV fistula, and that
< 10% of HD patients should be dialysed via
vascular catheters for > 3 months without a
maturing permanent VAS.
Most (> 70%) SUMC patients were treated by
fistula, compared to 31% of CDC patients. The
respective rates for vascular catheters were 15.4%
and 28.2%. Whereas fistulas appear to be the
major type of VAS used in Europe and Japan, AV
grafts are still the preferred VAS in the USA [12].
As of December 2001, fistulas comprised 30.4% of
VASs in the USA, but this number represents an
increase from lower rates (c. 22%) documented
5 years earlier, before the implementation of the
National Kidney Foundation guidelines [13]. In
addition, of 18 HD networks surveyed by the
CDC, only two had a fistula prevalence of > 40%
[13]. These differences accentuate the need to
consider VAS-specific infection rates while per-
forming surveillance, as overall infection rates
may over- or underestimate the need for an
infection control intervention in the HD popula-
tion.
Comparison of VAS-specific incidence rates
from the SUMC and CDC data revealed several
trends. First, the incidence of hospital admission
was significantly lower in SUMC for every given
VAS. Second, for cuffed catheters only, the inci-
dence of intravenous antibiotic therapy was sig-
nificantly lower in SUMC patients; a lower
incidence, but not significantly so, was shown
with other types of VAS. Therefore, it can be
speculated that the lower incidence of hospitali-
sation (but not antibiotic therapy) is the result of
different admission policies or a different inci-
dence of non-infectious disorders. Alternatively,
inappropriate antibiotic use may explain a similar
incidence of antibiotic administration in spite of
the lower incidence of hospitalisations. The high
rate of fever in this study cohort without an
infectious focus (c. 77%) supports this possibility.
Third, a significantly lower incidence of BSI
and ⁄ or VAS infection was observed for the SUMC
patients with fistulas, cuffed catheters and non-
cuffed catheters, but not for those with grafts. The
lower incidence of VAS-specific BSI and VAS
infection suggests that other factors (besides
distribution of VAS type), either intrinsic (as
discussed previously) or extrinsic (e.g., infection
control practices), may have influenced the risk of
infection in this patient population. HD patients
dialysed using grafts represent a subset of
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patients for whom further efforts to prevent
infection may be worthwhile in this institution.
VAS infections are caused mainly by Gram-
positive bacteria, especially staphylococci and
enterococci [5]. HD patients have played a prom-
inent role in the epidemic of vancomycin resist-
ance, and have been reported to comprise up to
one-quarter of hospitalised patients infected or
colonised with vancomycin-resistant Enterococcus
spp. [14,15]; indeed, HD patients were the most
prominent risk group among the first identified
cases of vancomycin intermediately-resistant
S. aureus [16]. Other resistant pathogens isolated
from HD patients include MRSA and multiresist-
ant Gram-negative non-fermentative bacilli [5].
Vancomycin is used commonly in HD patients
[17], as it can be administered conveniently to
patients during HD treatments, even though
reasonable alternatives exist [18]. The present
study showed that vancomycin is used frequently
(c. 25% of antibiotic courses) in SUMC for HD
patients admitted with suspected infection. How-
ever, in retrospect, vancomycin therapy was
completely appropriate in only two cases (of
MRSA BSI). BSI caused by MRSA comprised
12.5% of BSI cases, 4% of admissions with
suspected or proven infection, and 1.3% of
overall admissions. Therefore, routine empirical
use of vancomycin in this patient population
seems unjustified. Failure to use vancomycin
appropriately may result in the selection of
glycopeptide-resistant Gram-positive bacteria
[19]. Optimisation of the antibiotic policy for
infected HD patients is required, given that
empirical anti-staphylococcal therapy with cefaz-
olin may prove to be an adequate alternative and
has been recommended previously in this setting
[5]. Empirical vancomycin therapy should be
reserved for patients at high risk of MRSA
infection (e.g., those known to be colonised with
MRSA) or in life-threatening situations.
There are few data regarding HD-associated
infection in Israel. Only one recent paper has
focused on HD-associated infections; 67 HD
patients with BSI were compared to non-HD BSI
patients in a case-control study [20], which eval-
uated the influence of HD on the risk-factors,
bacteriology and outcome of bacteraemic patients.
Current surveillance data from Israeli hospitals
are lacking, even though the CDC have advocated
periodic surveillance of HD-associated infections
[5].
In conclusion, surveillance of HD-associated
infections in southern Israel revealed signifi-
cantly lower incidences of hospital admission,
intravenous antibiotic therapy, BSI and VAS
infection compared to CDC data. These differ-
ences may be attributed, at least in part, to the
different distribution of VAS types (a high rate
of AV fistulas and a low rate of vascular
catheters) in this study population. The
observed differences in VAS-specific incidents
may be related to intrinsic or extrinsic factors
and warrant further study. The present study
highlights the importance of reporting regional
and national HD-associated infection surveil-
lance data, especially VAS-specific incidents, as
comparisons of general incidence with interna-
tional benchmarks may be hampered by differ-
ences in population characteristics.
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